CY1119956T1 - Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου - Google Patents

Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου

Info

Publication number
CY1119956T1
CY1119956T1 CY20181100189T CY181100189T CY1119956T1 CY 1119956 T1 CY1119956 T1 CY 1119956T1 CY 20181100189 T CY20181100189 T CY 20181100189T CY 181100189 T CY181100189 T CY 181100189T CY 1119956 T1 CY1119956 T1 CY 1119956T1
Authority
CY
Cyprus
Prior art keywords
cancer
monoclonic
metastatic
cancer treatments
lung
Prior art date
Application number
CY20181100189T
Other languages
English (en)
Inventor
Ugur Sahin
Özlem TÜRECI
Michael Koslowski
Rita Mitnacht-Kraus
Original Assignee
Johannes-Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes-Gutenberg-Universität Mainz filed Critical Johannes-Gutenberg-Universität Mainz
Publication of CY1119956T1 publication Critical patent/CY1119956T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει αντισώματα χρήσιμα ως θεραπευτικά μέσα για την αντιμετώπιση ή/και πρόληψη ασθενειών που σχετίζονται με κύτταρα που εκφράζουν το GT468, συμπεριλαμβανομένων ογκοσχετικών νόσων όπως, Καρκίνος του μαστού, Καρκίνος πνευμόνων, γαστρικός Καρκίνος, Καρκίνος ωοθηκών, ηπατοκυτταρικός Καρκίνος, Καρκίνος παχέος εντέρου, παγκρεατικός Καρκίνος, οισοφαγικός Καρκίνος, Καρκίνος κεφαλής και αυχένα, Καρκίνος νεφρών, ιδιαίτερα νεφροκυτταρικό Καρκίνωμα, Καρκίνος του προστάτη, καρκίνος του ήπατος, μελάνωμα, σάρκωμα, μυέλωμα, νευροβλάστωμα, χοριοκαρκίνωμα πλακούντα, καρκίνος του τραχήλου και θυρεοειδής Καρκίνος όπως και οι μεταστατικές μορφές των ανωτέρω. Σε μία ενσωμάτωση, η εν λόγω νόσος είναι μεταστατικός καρκίνος πνευμόνων.
CY20181100189T 2008-09-16 2018-02-15 Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου CY1119956T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
PCT/EP2009/006704 WO2010031551A2 (en) 2008-09-16 2009-09-16 Monoclonal antibodies for treatment of cancer
EP09778564.6A EP2342234B1 (en) 2008-09-16 2009-09-16 Monoclonal anti-gt468 antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
CY1119956T1 true CY1119956T1 (el) 2018-12-12

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100189T CY1119956T1 (el) 2008-09-16 2018-02-15 Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου

Country Status (26)

Country Link
US (1) US8946388B2 (el)
EP (3) EP2166021A1 (el)
JP (1) JP2012502938A (el)
KR (1) KR101818741B1 (el)
CN (3) CN105753988A (el)
AU (1) AU2009294896B2 (el)
BR (1) BRPI0918178B8 (el)
CA (1) CA2732594C (el)
CY (1) CY1119956T1 (el)
DK (1) DK2342234T3 (el)
ES (1) ES2659718T3 (el)
HK (1) HK1253579A1 (el)
HR (1) HRP20180262T1 (el)
HU (1) HUE036477T2 (el)
IL (2) IL211010A (el)
LT (1) LT2342234T (el)
MX (2) MX2011002856A (el)
NO (1) NO2342234T3 (el)
NZ (2) NZ591004A (el)
PL (1) PL2342234T3 (el)
PT (1) PT2342234T (el)
RS (1) RS56937B1 (el)
SI (1) SI2342234T1 (el)
TR (1) TR201802090T4 (el)
WO (1) WO2010031551A2 (el)
ZA (1) ZA201100835B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PL2665749T3 (pl) * 2011-01-19 2016-06-30 Cantargia Ab Przeciwciała anty-il1rap i ich zastosowanie do leczenia guzów litych
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
PE20211760A1 (es) 2013-10-18 2021-09-07 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma) que comprenden grupos carboxilicos y una region de enlazador modificada, agentes formadores de imagenes y agentes farmaceuticos que los comprenden
EP3143045A1 (en) * 2014-05-12 2017-03-22 Numab AG Novel multispecific molecules and novel treatment methods based on such multispecific molecules
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
EP3322484B1 (en) * 2015-07-14 2021-03-24 Medimmune, LLC Method for detecting cancer stem cells
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
JP2019501151A (ja) * 2015-12-01 2019-01-17 ゲンマブ ビー．ブイ． 抗デスレセプター抗体およびその使用方法
AU2017332960B2 (en) * 2016-10-20 2019-09-12 I-Mab Biopharma Co., Ltd. Novel CD47 monoclonal antibodies and uses thereof
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
WO2018165895A1 (zh) * 2017-03-15 2018-09-20 苏州银河生物医药有限公司 Ctla4抗体、其药物组合物及其用途
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7129084B2 (en) 2000-08-03 2006-10-31 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
EP2316856B1 (en) 2002-10-17 2017-08-09 Genmab A/S Human monoclonal antibodies against CD20
CA2513292C (en) 2003-01-17 2016-04-05 The Chinese University Of Hong Kong Circulating mrna as diagnostic markers for pregnancy-related disorders
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
MX345316B (es) 2009-02-20 2017-01-23 Ganymed Pharmaceuticals Ag Métodos y composiciones para diagnóstico y tratamiento del cáncer.
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
CN102164963A (zh) 2011-08-24
AU2009294896A1 (en) 2010-03-25
CN104628858B (zh) 2018-11-16
HK1253579A1 (zh) 2019-06-21
CN102164963B (zh) 2015-07-29
HUE036477T2 (hu) 2018-07-30
BRPI0918178A2 (pt) 2015-12-01
IL211010A0 (en) 2011-04-28
EP3312198A1 (en) 2018-04-25
KR20110055699A (ko) 2011-05-25
US8946388B2 (en) 2015-02-03
PT2342234T (pt) 2018-02-21
WO2010031551A2 (en) 2010-03-25
KR101818741B1 (ko) 2018-01-15
TR201802090T4 (tr) 2018-03-21
MX2011002856A (es) 2011-06-28
ES2659718T3 (es) 2018-03-19
WO2010031551A3 (en) 2010-09-16
DK2342234T3 (en) 2018-02-26
NZ596490A (en) 2013-05-31
IL242204B (en) 2020-09-30
US20110223182A1 (en) 2011-09-15
CN105753988A (zh) 2016-07-13
SI2342234T1 (en) 2018-04-30
NO2342234T3 (el) 2018-04-14
HRP20180262T1 (hr) 2018-03-23
JP2012502938A (ja) 2012-02-02
EP2342234B1 (en) 2017-11-15
IL211010A (en) 2015-11-30
EP2166021A1 (en) 2010-03-24
RS56937B1 (sr) 2018-05-31
CN104628858A (zh) 2015-05-20
NZ591004A (en) 2012-03-30
PL2342234T3 (pl) 2018-07-31
LT2342234T (lt) 2018-03-12
IL242204A0 (en) 2015-11-30
BRPI0918178B8 (pt) 2021-05-25
CA2732594A1 (en) 2010-03-25
EP2342234A2 (en) 2011-07-13
BRPI0918178A8 (pt) 2020-05-19
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
MX357010B (es) 2018-06-22
ZA201100835B (en) 2014-04-30
BRPI0918178B1 (pt) 2021-04-06

Similar Documents

Publication Publication Date Title
CY1119956T1 (el) Μονοκλωνικα anti-gt468 αντισωματα για θεραπεια καρκiνου
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
CY1120300T1 (el) Αντισωματα ειδικα στην κλαουδινη 6 (cldn6)
CY1119738T1 (el) Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων
CY1122091T1 (el) Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων
CY1120267T1 (el) Αντισωματα ανταγωνιστες κατευθυνομενα εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης για την θεραπευτικη αγωγη αθροιστικης κεφαλαλγιας
CY1118608T1 (el) Αντισωματα για θεραπευτικη αγωγη καρκινου που εκφραζει κλαυδινη 6
CY1120123T1 (el) Μονοκλωνικα αντισωματα κατα της gt468 για τη θεραπεια του καρκινου
CY1119217T1 (el) Ενωση για την αγωγη του καρκινου
CY1119901T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1119799T1 (el) Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
CY1116847T1 (el) Ειδικοι ανταγωνιστες του υποδοχεα fgf-r4
CY1116886T1 (el) C-met αντισωματα
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CY1115178T1 (el) Βιοδεικτες καρκινου
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
CY1122156T1 (el) Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων
CY1119549T1 (el) Συνδυαστικη θεραπεια που περιλαμβανει αντισωματα κλωντινης 18.2 για τη θεραπεια του καρκινου
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis